March 2010 April 2010 May 2010 June 2010 July 2010
August 2010
September 2010 October 2010
November 2010
December 2010
January 2011
February 2011 March 2011 April 2011 May 2011 June 2011 July 2011 August 2011 September 2011 October 2011 November 2011 December 2011 January 2012 February 2012 March 2012 April 2012 May 2012 June 2012 July 2012 August 2012 September 2012 October 2012 November 2012 December 2012 January 2013 February 2013 March 2013 April 2013 May 2013 June 2013 July 2013 August 2013 September 2013 October 2013 November 2013 December 2013 January 2014 February 2014 March 2014 April 2014 May 2014 June 2014 July 2014 August 2014 September 2014 October 2014 November 2014 December 2014 January 2015 February 2015 March 2015 April 2015 May 2015 June 2015 July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016 May 2016 June 2016 July 2016 August 2016 September 2016 October 2016 November 2016 December 2016 January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 January 2018 February 2018 March 2018 April 2018 May 2018 June 2018 July 2018 August 2018 September 2018 October 2018 November 2018 December 2018 January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 September 2019 October 2019 November 2019 December 2019 January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 September 2020 October 2020 November 2020 December 2020 January 2021 February 2021 March 2021 April 2021 May 2021 June 2021 July 2021 August 2021 September 2021 October 2021 November 2021 December 2021 January 2022 February 2022 March 2022 April 2022 May 2022 June 2022 July 2022 August 2022 September 2022 October 2022 November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023 December 2023 January 2024 February 2024 March 2024
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
30
31
News Every Day |

Moderna's mRNA technology could help in the decades-long search for an HIV vaccine

Moderna vaccine
Biotechnology company Moderna protocol files for COVID-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida, on August 13, 2020.
  • Moderna's mRNA tech could change the game in the decades-long effort to develop an HIV vaccine.
  • The company said it expects to begin two vaccine trials in humans by the end of 2021.
  • While "excited" by the prospect, HIV researchers caution there's a long road ahead for mRNA vaccines.
  • See more stories on Insider's business page.

Moderna's investor presentation on Wednesday showcased the Massachusetts-based biotech's efforts to develop vaccines against HIV and eight other infectious diseases.

The company's mRNA technology, which has built upon decades of research, will now contribute to the long frustrated effort to contain the global HIV/AIDS epidemic.

Working in collaboration with the National Institutes of Health, Scripps Research, the Gates Foundation, and other partners, Moderna said it would begin testing two HIV vaccine candidates in humans by the end of 2021.

The COVID-19 vaccine developer's long-term goal is to show that its mRNA-based vaccine can produce broadly neutralizing antibodies, a type of immune response that researchers believe will be protective against circulating HIV strains around the world.

"Think about the people who die of HIV every year, the people who aren't alive because they don't have the amazing therapy available in this country," CEO Stephane Bancel told Insider in an interview Tuesday. In 2019, 700,000 people died of AIDS-related causes, the disease caused by HIV, and an estimated 1.7 million individuals contracted HIV.

However, two veteran HIV/AIDS researchers told Insider that while they're excited by the prospect of using mRNA technology to develop an HIV vaccine, there's a long road ahead for all players involved. Moderna's mRNA technology will indisputably speed up the "fine-tuning" of HIV vaccine development, but only continued testing will show if the end result is actually safe and effective.

Emory University virology professor Rafick-Pierre Sekaly, who has studied HIV for two decades, said it would be "crazy not to test" whether mRNA technology could bypass the expensive, slow process of generating these protein fragments in the lab.

"We had such a spectacular outcome with coronavirus that we absolutely need to embark on this platform and test it," Sekaly said. "None of the other [HIV] platforms have generated any inkling of promising results."

Read more: Moderna is betting its mRNA technology will lead to a new wave of vaccines for diseases like HIV. Here are the top 5 it's working on beyond COVID-19.

Moderna's partnership will build on a new and unproven vaccine approach

William Schief, an immunology professor at Scripps Research and vaccine design director of the International AIDS Vaccine Initiative, presented Moderna's investors with unpublished data from an HIV vaccine trial presented at a virtual AIDS research conference in February.

The trial, which started in 2018, was conducted with 48 HIV-negative adults, and will serve as preliminary basis off which Moderna and its collaborators will further study and test a vaccine approach targeting broadly neutralizing antibodies. Subjects were given either a low or high dose of the protein-based vaccine candidate, which was designed to activate certain "naive" B cells of the immune system.

When activated, the B cells produce proteins that eventually give rise to the hoped-for broadly neutralizing antibodies.

"The importance of priming these naive B cells is the key first step," Schief said on the investor call. "If you can't get that to work, the whole thing isn't going to work."

After being treated with the experimental vaccine, 47 out of 48 participants showed the targeted levels of naive B cells critical in eventually producing the antibodies, though the data remains subject to peer review. The final study volunteer dropped out.

Moderna's cost and time-efficient mRNA technology will speed up the process of conducting clinical trials, Schief said. Relatively speaking, conventional in-lab protein manufacturing is slow and expensive.

"It took us years just to do that one trial, many years," he added, referring to 48-person study. "We need to do a lot of human clinical trials, and we think that Moderna mRNA is the technology that will let us do that."

Moderna plans to test two mRNA-delivered HIV vaccine candidates in humans, both of which will test for safety and efficacy. The first is based on the initial study's protein component, while the other will determine whether synthetic HIV-like antigens can provoke the desired immune response. Both trials will start by the end of this year.

Stephane Bancel
Moderna CEO, Stephane Bancel attends 2019 Forbes Healthcare Summit at the Jazz at Lincoln Center on December 05, 2019 in New York City.

Compared to the virus behind COVID-19, HIV is a 'very different ballgame'

Dr. Ian Frank, an HIV vaccine researcher at the University of Pennsylvania who's helped develop HIV vaccines including one that made it to late-stage trials in 2007, said that the mRNA approach to developing an HIV vaccine has the advantage of speed and flexibility. Without scrutinizing the data from Schief's study, which is still undergoing peer review, it's a little difficult to understand the nuance, he said.

However, if the data show the vaccine created broadly neutralizing antibodies, this approach would signal a complete paradigm shift for HIV vaccine research, Frank said.

Despite the success of using mRNA to immunize against COVID-19, HIV is a "very different ballgame," Sekaly, the HIV researcher at Emory University, said. Once infected with HIV, the virus remains permanently active in a small number of cells in the body if left untreated, unlike the virus that causes COVID-19.

This means that a successful HIV vaccine has to overcome a higher hurdle than any other vaccine in history, Frank said. It would need to prevent infection, or the immune response underlying it, entirely. Other vaccines, including both Moderna and Pfizer-BioNTech's COVID-19 vaccines, only prevent the development of an infection into illness.

"For us to have an HIV vaccine that is effective in a way that will lead to prevention of infection, there's some fine tuning of this vaccine that is gonna need to happen," Frank said.

Although "excited" by the prospect of the Moderna partnership in HIV vaccine trials, Sekaly stressed that the mRNA-based delivery approach is still unproven beyond COVID-19, and emphasized the need for patient safety in clinical trials.

Both Frank and Sekaly said that the company's mRNA platform would likely enable any promising vaccine candidates to move from early to mid-stage clinical trials within a year - a much faster pace than vaccine development has historically gone.

Moderna's mRNA candidates have breakthrough potential in the frustrating, costly search for an HIV vaccine

Speaking to Insider, company CEO Bancel acknowledged the inherent challenge in developing a safe and effective HIV vaccine, a global health problem whose solution has eluded researchers for four decades.

The last HIV vaccine candidate that had made it to late-stage studies in South Africa stopped in February 2020 after there was "absolutely no evidence of efficacy," its head researcher told Science.

An earlier version of the vaccine used in the South African study had only shown 31% efficacy in a previous trial in Thailand. Before that, the last HIV vaccine to make it to a late-stage clinical trial concluded in 2007.

The two remaining late stage clinical HIV vaccines trials, Mosaico and Imbokodo, are being run by Johnson & Johnson and will not release results before the end of 2021.

Like the South African study halted in 2020, both trials use an inactive viral vector carrying genetic material based on HIV's many strains from around the world, as well as a synthetic protein mimicking part of a particle's envelope protein.

Even without Moderna involved, the HIV vaccine designed by Schief's team takes a different approach to tackling the virus than the one used in the J&J trials. By using the same delivery method as both Moderna's and Pfizer-BioNTech's COVID-19 vaccines, researchers will be able to fine-tune versions of their vaccine even further, Frank said.

AP21034450685389
A Palestinian medic displays a vial of the Moderna COVID-19 vaccine.

COVID-19 vaccines have benefited from decades of HIV vaccine research

Although he finds the prospect of an mRNA vaccine exciting, Frank said Moderna and its partners have a long road ahead in proving if their mRNA-delivered protein approach is successful.

"The strategy has the potential to be a breakthrough, but it's the first step in a hard climb," Frank said. Moderna's mRNA technology will definitely give researchers the ability to test quickly, but that's all he can conclude.

"I'm sure they can get a candidate vaccine," Frank said. "The challenge will be how effective of an immune response it elicits."

The COVID-19 were been the breakthrough moment for mRNA vaccines, creating inroads for further HIV and cancer research. However, according to a recent National Bureau of Economic Research paper, it was actually decades of collective failure and the billions of dollars poured into HIV vaccine research that laid the foundation for the COVID-19 vaccines.

Published in March, author Jeffrey E. Harris found that 86% of clinical COVID-19 vaccines could trace their scientific basis to past HIV vaccine trials. From this vantage point, Moderna's mRNA platform is actually just a brief interlude from directly HIV-oriented scientific research driving the latest efforts in curbing the HIV/AIDS epidemic.

Andrew Dunn contributed reporting.

Read the original article on Business Insider
Сергей Лавров

Лавров заявил, что сфер сотрудничества России и Запада практически не осталось

Top 10 Emmanuelle Seigner Movies

Top 10 Love Affair Movies of the 2000s and 2010s

Top 5 Websites to Watch FREE Movies - TV Shows (No Sign up!)

The 10 Intense New Action Movies on Netflix That Left Me on the Edge of My Seat!

Ria.city






Read also

Tom Holland Enjoys New York City as Girlfriend Zendaya Promotes Her Movie in Australia

Army chiefs overturn century-old ban on beards with backing from King Charles

Scientists’ group names Filipina in Germany as ‘Planet Earth’ awardee

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

I was diagnosed with cancer aged 39… you are never too rich, too famous or too young, says Dr Philippa Kaye

Today24.pro — latest news 24/7. You can add your news instantly now — here


News Every Day

Top 5 Websites to Watch FREE Movies - TV Shows (No Sign up!)



Sports today


Новости тенниса
WTA

Азаренко вышла в полуфинал турнира WTA-1000 в Майами



Спорт в России и мире
Москва

«Радио Зенит» – информационный партнер форума «Мы вместе. Спорт»



All sports news today





Sports in Russia today

Москва

Блиц-матч по шахматам между двумя командами провели в павильоне «Спорт для каждого»


Новости России

Game News

Teeny Tiny Trains — новая мобильная игра по типу Railbound


Russian.city


Москва

Благотворительный фонд «Свет в руках» проведет Всероссийскую акцию «Росток памяти»


Губернаторы России
Арцах

Грязная азербайджанская пропаганда на трагедии россиян


Шапки женские вязаные на Wildberries, 2024 — новый цвет от 392 руб. (модель 466)

Заказать недорогой ремонт шкафов купе в Москве и Московской области

Заказать недорогой ремонт кухонной мебели в районе в Москве и Московской области

Путин заявил, что для России важнее всего отношения с ближайшими соседями


EMIN, Баста, Полина Гагарина, Валерия и другие артисты исполнили песни Муслима Магомаева

Концерт благотворительного фонда Владимира Спивакова прошел в Солнечногорске

Семен Слепаков решил избавиться от последнего бизнеса в России

Кто из российских звезд перевел миллионы рублей жертвам «Крокуса»: сколько пожертвовали SHAMAN, Моргенштерн*, Бузова, Крид, INSTASAMKA, «Пикник» и другие


Хачанов победил Черундоло и пробился в 1/8 финала турнира ATP в Майами

Рыбакина о том, что не играла в Индиан-Уэллс из-за болезни: «К сожалению, восстановление заняло много времени»

Теннисист Медведев вышел в полуфинал турнира в Майами, обыграв Харри

Виктория Азаренко вышла в полуфинал турнира WTA-1000 в Майами



«Радио Зенит» – информационный партнер форума «Мы вместе. Спорт»

Перенос дат II этапа культурного проекта «Классика: история и современность» в Дмитрове

Архитектурные доминанты округов Москвы

Шапки женские вязаные на Wildberries, 2024 — новый цвет от 392 руб. (модель 466)


Фильм Джонни Деппа о Модильяни покажут в России

ТНТ запускает ежедневное утреннее шоу с Анной Хилькевич и Анатолием Цоем

Тема дня: Путин поручил комиссии по НТР представить перечень приоритетных направлений

Всем по местам: в России назвали топ благополучных регионов


В городской гимназии № 7 Брянска состоялась акция «Сдаём вместе.День сдачи ЕГЭ родителями»

Голикова: число обращений за помощью от пострадавших в «Крокусе» может вырасти

В усадьбе «Измайлово» открылась выставка строгановской школы керамики

Инцидент с растоптанным флагом у Кремля получил продолжение: В дело вмешался СК



Путин в России и мире






Персональные новости Russian.city
Концерт

Концерт группы "Пикник" начался с минуты молчания в память о погибших в "Крокусе"



News Every Day

Top 10 Emmanuelle Seigner Movies




Friends of Today24

Музыкальные новости

Персональные новости